Medicare Anti-A β mAb Coverage With Evidence Development (CED) Study

Conditions:   Mild Alzheimer's Disease;   Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease Intervention:   Drug: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Sponsor:   Centers for Medicare and Medicaid Services/ Coverage and Analysis Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials